Mannkind Corporation (NASDAQ:MNKD) to present at the healthcare conference
Mannkind Corporation (NASDAQ:MNKD) primarily engaged in the development and commercialization of therapeutic products for the treatment of diseases such as diabetes and cancer. The development stage bio pharmaceutical company had completed the Phase III clinical trials for its drug candidate AFREZZA, which had been developed as an ultra rapid action meal time insulin inhalation powder.
Study 171, which is an open label study of the insulin drug AFREZZA was conducted on patients with Type I diabetes. The drug developed for the control of hyperglycemia had proved to be successful with the completion of follow up visits of patients who were administered with the drug. The study was conducted in two treatment groups and the safety profile of the groups was compared.
Further, Mannkind Corporation (NASDAQ:MNKD) also conducted experimental researches through meal time injection of the ultra rapid action drug AFREZZA and the results of the treatment was then iterated for the patients. The drug had been developed as a drug device combination product, which consists of the inhalation powder, AFREZZA, the pre metered single use cartridges and light, discreet, easy to use inhaler.
Once the drug is administered to the patient at the meal time, AFREZZA acts at rapid pace to mix insulin into the bloodstream. Just in 12 to 14 minutes of administration, the insulin levels would reach peak levels. The drug AFREZZA had by now been tested in around 5600 adult patients in 61 clinical studies. Mannkind Corporation (NASDAQ:MNKD) has planned to present the results of Phase III clinical studies of the drug AFREZZA at the Healthcare Conference 2013 of Wells Fargo Securities Research and Economics to be held on June 18, 2013.
The shares of the development stage bio pharmaceutical company, Mannkind Corporation (NASDAQ:MNKD) had been surging in share prices in the recent days with heavy trading volumes. The shares of the company had surged by 2.01 percent to close at $7.65 per share for the last trading session on Tuesday. Mannkind Corporation (NASDAQ:MNKD) had witnessed the trade of 13.64 million shares on Tuesday, while the average trading volume is at 8.51 million shares per day.